IRCT2016091029777N1已完成2 期
A double blind clinical trial on the effect of saffaron tablet on changing level of inflammatory markers Interleukin 1 beta(IL1ß) and Tumor necrosis factor alpha(TNFa) in patients with Knee osteoarthritis
Vice chancellor for research, Golestan University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50 years 至 70 years（—）
- 性别
- All
入选标准
- •Knee osteoarthritis patients based on American College of Rheumatology(ACR) diagnostic criteria with an intensity of 2 to 3 according to Kellgren and Lawrence(KL) radiography grade, Patients with an average age of 50 to 70 years old;
- •Exclusion criteria: Known hypersensitivity to Saffron, Patients with other rheumatologic diseases, Patients with active malignant disease or infection, Patients with known mental illness, Patients with a history of recent Knee surgery and severe trauma(within 6 months), Patients with hip osteoarthritis, Patients with septic arthritis, Patients with active gastrointestinal bleeding or a history of it, Patients with chronic kidney disease when the estimated Glomerular Filtration Rate(GFR) is less than 30 ml/min/1.73m2, Severe leukopenia, Patients requiring long term use of corticosteroids such as asthma or inflammatory bowel disease.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A study comparing the safety and effects of a compound ACI-91 with placebo in patients with mild to moderate Alzhiemer's diseaseMild to moderate Alzheimer’s DiseaseMedDRA version: 14.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2008-005260-14-DEAC Immune SA64
进行中（未招募）
不适用
A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months’ treatment with ACI 91 in patients with mild to moderate Alzheimer’s Diseasemild to moderate Alzheimer’s DiseaseMedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2008-005260-14-ATAC Immune SA60
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseEUCTR2006-004111-22-GRovartis Pharma Services AG146
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseCushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to produce excess cortisol, leading to the subsequent development of the clinical signs and symptoms of hypercortisolism. Cushing's disease is associated with severe morbidity and premature mortality and most commonly affects adults aged 20-50, primarily femalesMedDRA version: 8.1Level: LLTClassification code 10011651Term: Cushing's diseaseEUCTR2006-004111-22-DEovartis Pharma Services AG100
进行中（未招募）
不适用
A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s diseaseMedDRA version: 8.1Level: LLTClassification code 10011651Term: Cushing's diseaseCushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to produce excess cortisol, leading to the subsequent development of the clinical signs and symptoms of hypercortisolism. Cushing's disease is associated with severe morbidity and premature mortality and most commonly affects adults aged 20-50, primarily femalesEUCTR2006-004111-22-DKovartis Pharma Services AG146